



IFW

Docket No.: 0020-5489PUS1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Robert William WARD et al.

Application No.: 10/581,723

Confirmation No.: 8547

Filed: June 5, 2006

Art Unit: N/A

For: NOVEL COMPOUNDS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL
REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE
1.114 RCE APPLICATION)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

☒ a. Copies of cited U.S. patents and patent application publications are not included.
Copies of foreign patent documents and non-patent literature are included.

☐ b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

☐ c. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s) and U.S. Filing Date

PCT/JP2004/019455 filed December 17, 2004

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

☒ a. DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

☐ b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

☐ c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

☐ d. OTHER - The following additional information is provided for the Examiner's consideration.

IV. FEES (check one box)

☐ a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

☐ b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

☐ c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required.
(This section is not to be used with RCE's.)

☐ d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

☐ e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

☒ f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

☐ g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

☐ No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.

or

☒ See the statement below. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(e)

(check only one box)

The undersigned hereby states that:

☐ a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

☐ b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

☐ d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)


- ☐ The required fee is listed on the attached Fee Transmittal.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.


Dated: December 18, 2006

Respectfully submitted,

By 
Gerald M. Murphy, Jr.
Registration No.: 28,977
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachment(s):

- ☒ PTO-SB08
☒ Documents
☐ Foreign Search Report
☐ Fee
☐ Other:



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/581,723-Conf. #8547
				Filing Date	June 5, 2006
				First Named Inventor	Robert William WARD
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	0020-5489PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-02/18320-A	03-07-2002			
	BB	WO-00/37444	06-29-2000			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Gm

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Birch, Stewart, Kolasch & Birch, LLP

GMM/jg

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/581,723-Conf. #8547
				Filing Date	June 5, 2006
				First Named Inventor	Robert William WARD
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	0020-5489PUS1

	CR	Andrew, David P., et al., "Distinct but Overlapping Epitopes are Involved in $\alpha 4\beta 7$ -Mediated Adhesion to Vascular Cell Adhesion Molecule-1, Mucosal Addressin-1, Fibronectin, and Lymphocyte Aggregation", The Journal of Immunology, Vol. 153, pgs. 3847-3861, (1994).	
	CS	Briskin, Michael J., et al., "MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to 1gA1", Nature, Vol. 363, pgs. 461-464, (1993).	
	CT	Shyjan, Anne M., "Human Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Demonstrates Structural and Functional Similarities to the $\alpha 4\beta 7$ -Integrin Binding Domains of Murine MAdCAM-1, but Extreme Divergence of Mucin-Like Sequences, The Journal of Immunology, Vol. 156, pgs. 2851-2857, (1996).	
	CU	Berg et al., "Homing Receptors and Vascular Addressins: Cell Adhesion Molecules that Direct Lymphocyte Traffic", Immunological Reviews, No. 108, pgs. 5-18, (1989).	
	CV	Holzmann, et al., "Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4 α ", Cell, Vol. 56, pgs. 37-46, (January 1989).	
	CW	Cheng, Yung-chi and Prusoff, William H., "Relationship Between the Inhibition Constant (KI) and the Concentration of Inhibitor which causes 50 per cent Inhibition (I50) of an Enzymatic Reaction", Biochemical Pharmacology, Vol. 22, pgs. 3099-3108, (1973).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/581,723-Conf. #8547
				Filing Date	June 5, 2006
				First Named Inventor	Robert William WARD
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	0020-5489PUS1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Butcher, Eugene C., "Leukocyte-Endothelial Cell Recognition: Three (or More) Steps to Specificity and Diversity", Cell, Vol. 67, pgs. 1033-1036, (1991).	
	CB	Harlan, John M., "Leukocyte-Endothelial Interactions", Blood, Vol. 65, No. 3, pgs. 513-525 (March 1985).	
	CC	Hemler, Martin E., "VLA Proteins in the Integrin Family: Structures, Functions, and Their Role on Leukocytes", Annu. Rev. Immunol., pgs. 365-400, (1990).	
	CD	Osborn, Laurelee, "Leukocyte Adhesion to Endothelium in Inflammation", Cell, Vol. 62, pgs. 3-6, (July 1990).	
	CE	Springer, Timothy A., "Adhesion receptors of the immune system", Nature, Vol. 346, pgs. 425-434, (August 1990).	
	CF	Springer, Timothy A., "Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm", Cell, Vol. 76, pgs. 301-314, (January 1994).	
	CG	Wayner, Elizabeth A. and Carter, William G., "Identification of Multiple Cell Adhesion Receptors for Collagen and Fibronectin in Human Fibrosarcoma Cells Possessing Unique α and Common β Subunits", The Journal of Cell Biology, Vol. 105, pgs. 1873-1884, (October 1987).	
	CH	Bornstein, Paul and Sage, Helene, "Structurally Distinct Collagen Types", Ann. Rev. Biochem., pgs. 957-1003, (1980).	
	CI	Miller, Edward J., "Chemistry of the Collagens and Their Distribution", The Department of Biochemistry and Institute of Dental Research, University of Alabama Medical Center, University Station, pgs. 41-81 (1983).	
	CJ	Hynes, Richard O., "Integrins: A Family of Cell Surface Receptors", Cell, Vol. 48, pgs. 549-554, (February 1987).	
	CK	Shimizu, Yoji et al., "Roles of Adhesion Molecules in T-Cell Recognition: Fundamental Similarities between Four Integrins on Resting Human T. Cells (LFA-1, VLA-4, VLA-5, VLA-6) in Expression, Binding, and Costimulation", Immunological Reviews, No. 114, pgs. 109-143, (1990).	
	CL	Hemler, Martin E., et al., "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides", The Journal of Biological Chemistry, Vol. 262, No. 24, pgs. 11478-11485, (1987).	
	CM	Bochner, Bruce S., et al., "Adhesion of Human Basophils, Eosinophils, and Neutrophils to Interleukin 1-activated Human Vascular Endothelial Cells: Contributions of Endothelial Cell Adhesion Molecules", J. Exp. Med., Vol. 173, pgs. 1553-1556, (June 1991).	
	CN	Ibbotson, Geoffrey C., et al., "Functional $\alpha 4$ -integrin: A newly identified pathway of neutrophil recruitment in critically ill septic patients," Nature Medicine, Vol. 7, No. 4, pgs. 465-470, (April 2001).	
	CO	Elices, Mariano J., et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site", Cell, Vol. 60, pgs. 577-584, (February 1990).	
	CP	Wayner, Elizabeth A., et al., "Identification and Characterization of the T Lymphocyte Adhesion Receptor for an Alternative Cell Attachment Domain (CS-1) in Plasma Fibronectin", The Journal of Cell Biology, Vol. 109, pgs. 1321-1331, (1989).	
	CQ	Bayless, Kayla J., et al., "Osteopontin is a ligand for the $\alpha 4 \beta 1$ integrin", Journal of Cell Science 111, pgs. 1165-1174, (1998).	
Examiner Signature			Date Considered